Last reviewed · How we verify
AP23573
At a glance
| Generic name | AP23573 |
|---|---|
| Also known as | deforolimus, MK-8669, ridaforolimus was also known as deforolimus until May 2009 |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease (NA)
- IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System (NA)
- IonMAN Trial- First in Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System (NA)
- BIONICS Small Vessels Trial EluNIR Ridaforolimus Eluting Coronary Stent System (EluNIR) in Coronary Stenosis Trial
- Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED) (PHASE1)
- Study of BioNIR Drug Eluting Stent System in Coronary Stenosis (NA)
- MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR) (NA)
- Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AP23573 CI brief — competitive landscape report
- AP23573 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI